Melanotransferrin: A “Missing Link” and a Novel Pharmacological Target for Treatment [ 2018 - 2020 ]

Research Grant

Researchers: Prof Des Richardson (Principal investigator) ,  Dr Darius Lane ,  Dr Yohan Suryo Rahmanto ,  Dr Zaklina Kovacevic

Brief description Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.

Funding Amount $AUD 622,441.86

Funding Scheme Project Grants

Notes Standard Project Grant